Literature DB >> 2210464

Reduction of gastric ulcer recurrence after suppression of Helicobacter pylori by cefixime.

M Tatsuta1, H Ishikawa, H Iishi, S Okuda, Y Yokota.   

Abstract

The effect on the recurrence of gastric ulcers after suppression of Helicobacter pylori by combined treatment with cimetidine and the antimicrobial drug cefixime was investigated. Twenty one of 43 patients with endoscopically proved gastric ulcer and H pylori infection were randomly assigned to receive cimetidine 800 mg daily for 12 weeks; the remaining 22 patients received cimetidine 800 mg daily for 12 weeks plus cefixime 100 mg daily for the last two weeks. After treatment, 88% of 17 patients on cimetidine only remained H pylori positive, whereas combined administration of cimetidine and cefixime had suppressed H pylori in 78% of 18 patients (p less than 0.05). Seventeen patients in the former group whose ulcers healed but who remained H pylori positive and 18 patients in the latter group whose ulcers healed and who were no longer infected with H pylori continued to be followed after treatment. These patients underwent endoscopy to detect ulcer recurrence if symptomatic, or at 12 and 24 weeks if asymptomatic. At 12 weeks, recurrence was observed in seven of 15 (47%) patients in whom H pylori persisted, but in only one of 14 (7%) patients in whom H pylori had been suppressed (p less than 0.05). At 24 weeks, however, recurrence rates were similar between the two groups. These findings indicate that H pylori infection may be closely related to early ulcer recurrence.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2210464      PMCID: PMC1378650          DOI: 10.1136/gut.31.9.973

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  13 in total

Review 1.  Campylobacter pyloridis, gastritis, and peptic ulceration.

Authors:  C S Goodwin; J A Armstrong; B J Marshall
Journal:  J Clin Pathol       Date:  1986-04       Impact factor: 3.411

2.  Unidentified curved bacilli on gastric epithelium in active chronic gastritis.

Authors:  J R Warren; B Marshall
Journal:  Lancet       Date:  1983-06-04       Impact factor: 79.321

3.  Double-blind short-term trial of furazolidone in peptic ulcer.

Authors:  Z T Zheng; Z Y Wang; Y X Chu; Y N Li; Q F Li; S R Lin; Z M Xu
Journal:  Lancet       Date:  1985-05-04       Impact factor: 79.321

4.  Furazolidone in peptic ulcer.

Authors:  H Y Zhao; G Z Li; J D Guo; Z Yan; S W Sun; L S Li; Y M Duan; F Z Yue
Journal:  Lancet       Date:  1985-08-03       Impact factor: 79.321

5.  Campylobacter like organisms on the gastric mucosa: culture, histological, and serological studies.

Authors:  D M Jones; A M Lessells; J Eldridge
Journal:  J Clin Pathol       Date:  1984-09       Impact factor: 3.411

6.  The gastro-duodenal epithelium in peptic ulceration.

Authors:  H W Steer
Journal:  J Pathol       Date:  1985-08       Impact factor: 7.996

7.  Tri-potassium di-citrato bismuthate: a report of its pharmacological properties and therapeutic efficacy in peptic ulcer.

Authors:  R N Brogden; R M Pinder; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976-12       Impact factor: 9.546

8.  Cimetidine, cigarette smoking, and recurrence of duodenal ulcer.

Authors:  S Sontag; D Y Graham; A Belsito; J Weiss; A Farley; R Grunt; N Cohen; D Kinnear; W Davis; A Archambault
Journal:  N Engl J Med       Date:  1984-09-13       Impact factor: 91.245

9.  Campylobacter pyloridis, urease, hydrogen ion back diffusion, and gastric ulcers.

Authors:  S L Hazell; A Lee
Journal:  Lancet       Date:  1986-07-05       Impact factor: 79.321

10.  Smoking and cancer of the alimentary tract in Poland.

Authors:  J Staszewski
Journal:  Br J Cancer       Date:  1969-06       Impact factor: 7.640

View more
  11 in total

Review 1.  Helicobacter pylori and peptic ulcers: the present position.

Authors:  S Moss; J Calam
Journal:  Gut       Date:  1992-03       Impact factor: 23.059

2.  Short-term treatment of gastric ulcer. A meta-analytical evaluation of blind trials.

Authors:  F Di Mario; G Battaglia; G Leandro; G Grasso; F Vianello; S Vigneri
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

3.  Familial clustering of Helicobacter pylori infection: population based study.

Authors:  P Dominici; S Bellentani; A R Di Biase; G Saccoccio; A Le Rose; F Masutti; L Viola; F Balli; C Tiribelli; R Grilli; M Fusillo; E Grossi
Journal:  BMJ       Date:  1999-08-28

4.  Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.

Authors:  Wei Fu; Zhiqiang Song; Liya Zhou; Yan Xue; Yu Ding; Baojun Suo; Xueli Tian; Li Wang
Journal:  Dig Dis Sci       Date:  2017-04-08       Impact factor: 3.199

5.  Cure of peptic gastric ulcer associated with eradication of Helicobacter pylori. Finnish Gastric Ulcer Study Group.

Authors:  K Seppälä; P Pikkarainen; P Sipponen; E Kivilaakso; M H Gormsen
Journal:  Gut       Date:  1995-06       Impact factor: 23.059

Review 6.  Eradication of Helicobacter pylori: therapies and clinical implications.

Authors:  H J O'Connor
Journal:  Postgrad Med J       Date:  1992-07       Impact factor: 2.401

7.  Helicobacter pylori infection in a pediatric population: in vitro susceptibilities to omeprazole and eight antimicrobial agents.

Authors:  V G Loo; P Sherman; A G Matlow
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

8.  Cloning, nucleotide sequence, and expression of a gene encoding an adhesin subunit protein of Helicobacter pylori.

Authors:  D G Evans; T K Karjalainen; D J Evans; D Y Graham; C H Lee
Journal:  J Bacteriol       Date:  1993-02       Impact factor: 3.490

Review 9.  Helicobacter pylori infection and its role in human disease--an overview.

Authors:  K E McColl
Journal:  Pharm World Sci       Date:  1996-04

10.  Antimicrobial therapies for Helicobacter pylori infection in gnotobiotic piglets.

Authors:  S Krakowka; K A Eaton; R D Leunk
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.